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Abstract 
Background:  Varenicline, a partial agonist at α4β2 and full agonist at α7 nicotinic cholinergic 
receptors, is FDA approved for treatment of smoking cessation and has been found to reduce 
alcohol craving in clinical populations.  In rodents, varenicline decreases free-choice ethanol intake 
with somewhat mixed findings in operant paradigms that utilize a combined 
appetitive/consummatory response.   
Methods:  The present experiment utilized an operant paradigm that procedurally separates 
appetitive from consummatory responding and a “reward blocking” approach (i.e., rats were able to 
consume ethanol during treatment) to better understand the efficacy of varenicline as a treatment 
for ethanol self-administration and subsequent ethanol-seeking.  Separate groups of ethanol- and 
sucrose reinforced alcohol preferring, male P rats experienced alternating cycles of vehicle (2-week 
cycles) and varenicline (0.3, 1.0 and 2.0 mg/kg self-administered in a gelatin preparation) treatment 
(3-week cycles) prior to daily sessions where a single lever-press resulted in 20 minutes of reinforcer 
access.  At the end of each cycle, a single extinction session assessed the seeking response in the 
absence of drug pretreatment.   
Results:  Varenicline dose-dependently decreased ethanol intake.  Sucrose intake was largely 
unaffected, with no overall treatment effects and only sporadic days where the medium and high 
dose differed from vehicle.  Neither sucrose nor ethanol-seeking was significantly decreased by 
varenicline, and there were no treatment effects on either lick or lever-press latency.  Overall effect 
sizes were much greater for both drinking and seeking in the Ethanol Group as compared to the 
Sucrose Group.  
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Conclusions:  Varenicline effectively attenuates ethanol self-administration during treatment, but 
the experience with ethanol consumption while varenicline is “on board” is not sufficient to alter 
subsequent ethanol-seeking.  The overall pattern of findings indicate that varenicline blocks the 
rewarding properties of ethanol while not substituting for ethanol, that the non-specific effects on 
an alternate reinforcer are negligible, and that blood levels of varenicline need to be maintained in 
order for treatment to remain effective.   
 
Introduction 
 Varenicline, a partial agonist at α4β2 and full agonist at α7 nicotinic cholinergic receptors, is 
FDA approved for treatment of smoking cessation and has been reported to be “more effective and 
satisfactory” by patients when compared with bupropion and nicotine replacement therapy, both of 
which are also approved for smoking cessation (Etter and Schneider, 2013).  As reviewed by Aubin et 
al. (2014), varenicline has the largest effect size of the approved treatments and extended treatment 
with varenicline may prevent relapse to smoking.  Serendipitous findings indicated that alcohol 
consumption was also decreased in individuals receiving varenicline treatment for smoking, and 
subsequent placebo-controlled clinical trials, one open-label study (Erwin and Slaton, 2014), and a 
large double-blind multi-site treatment trial (Litten et al., 2013) found varenicline to be efficacious at 
decreasing alcohol intake and alcohol craving.  A more recent study confirmed that varenicline 
decreased alcohol craving, but did not find a decrease in alcohol drinking relative to placebo (de 
Bejczy et al., 2015).     
In preclinical models, varenicline disrupts the discriminative effects of ethanol (Randall et al., 
2015), decreases home-cage and fixed-ratio reinforced ethanol intake (Steensland et al., 2007), and 
blocks reinstatement to ethanol seeking (Funk et al., 2016).  Systemic varenicline stimulates release 
of dopamine in the nucleus accumbens and direct administration of varenicline into the accumbens 
core decreases ethanol intake (Feduccia et al., 2014).  While varenicline does not block ethanol-
induced conditioned place preference, it decreases ethanol-induced locomotor stimulation 
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indicating that it does interact with some interoceptive effects of ethanol (Gubner et al., 2014), but 
importantly, it does not substitute for ethanol (Randall et al., 2015).  Prior research has repeatedly 
shown that orally self-administered varenicline decreases home-cage ethanol intake in alcohol-
preferring P rats: 1) following long term administration when it tested with a one-hour pretreatment 
time (Froehlich et al., 2016); 2) if it is given with the first opportunity to drink ethanol but not if it is 
given as a preventative treatment prior to onset of the first experience with ethanol (Froehlich et al., 
2017a); and 3) in cases when escalation in intake would normally be seen following ethanol 
deprivation and alcohol re-access (Froehlich et al., 2017b).      
The present study sought to extend these previous findings using our operant paradigm that 
was designed to model the experience of a heavy drinking individual on long-term treatment.  
Specifically, rats experienced three-week long cycles of varenicline treatment and daily operant 
sessions with a low response requirement that resulted in access to ethanol.  At the end of each 
varenicline treatment cycle, the rats were tested in a single extinction session to assess their seeking 
response.  We have previously used this seeking/drinking operant paradigm to demonstrate that 
naltrexone, one of the three drugs approved by the FDA for treating alcohol use disorders, 
selectively reduces ethanol-seeking as compared to sucrose-seeking in nondependent Long Evans 
rats (Czachowski and DeLory, 2009).  Interestingly, evidence suggests that naltrexone treatment may 
be more efficacious in patients who continue to drink some alcohol during treatment (Heinälä et al., 
2001; Killeen et al., 2004).  The interaction between consumed ethanol and naltrexone’s efficacy 
may be partially explained by a learned, associative component of a “disruption” of ethanol reward 
while continuing to drink during treatment (Stromberg et al., 1998).  The goal of the present study 
was to determine the efficacy of varenicline to reduce ongoing ethanol drinking as well as to reduce 
ethanol “craving-like” behavior in animals experienced with drinking ethanol during varenicline 
treatment.  To examine the specificity of varenicline’s effects, sucrose was used as an alternate 
reinforcer in a separate group of animals.   
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Materials and Methods 
Subjects 
 Subjects were alcohol-naïve male P rats from the 79th generation of selective breeding for 
alcohol preference  (obtained from the Indiana University School of Medicine, Indianapolis, IN) that 
were randomly assigned to either an ethanol-reinforced group or a sucrose-reinforced group 
(n=12/group).  Ad libitum access to food and water was maintained throughout the experiments 
except where noted below.  Training began at 8 weeks of age (weights: 208 +/-15 g).  Animals were 
individually housed on a 12-h light/dark cycle (5:00 a.m. to 5:00 p.m.), and all animal care 
procedures were conducted in accordance with the NIH Guidelines for the Care and Use of 
Laboratory Animals (2011), and all protocols were approved by the Institutional Animal Care and Use 
Committee (IACUC).   
 
Apparatus 
Daily sessions were conducted in modular chambers (Med-Associates; St. Albans, VT, USA; 
30×30×24.5 cm) equipped with a houselight, a retractable lever, and a retractable graduated 
cylinder tube with rubber stopper and a stainless steel spout with double ball bearings to prevent 
leakage.  The lever was located on the wall opposite to the sipper tube drinking bottle.  All chambers 
were housed in sound-attenuated enclosures equipped with exhaust fans that masked external 
noise.  Electrical inputs and outputs of each chamber were controlled using Med-Associates software 
(Med-Associates). 
 
Drugs 
 Ethanol solutions were prepared volume/volume in water from 95% ethanol.  The 
sucrose/ethanol solutions were prepared weight/volume using sucrose as the solute in the ethanol 
solution.  Varenicline (provided by Pfizer, Inc., USA) was incorporated into flavored star-shaped 
pieces of gelatin that were voluntarily consumed by the rats.  Varenicline was added to a sweetened 
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gelatin solution comprised of berry flavored Jell-O, gelatin, dextrose, sodium saccharin and 
Magnasweet in distilled, deionized water.  The gelatin solution, containing drug or no drug (vehicle), 
was aliquoted into star shaped molds, one per rat per day, with the volume of each aliquot 
determined by the body weight of the rat, as previously described (Froehlich et al., 2013; 2016; 
2017).  Gelatin stars (approximately 1.8 gram) were fed to the rats once each day inserted through 
the wire top of their home cage.  The rats consistently ate the gelatin within 1-2 minutes.  Cages 
were checked to confirm that no pieces of gelatin were uneaten.  On treatment days, gelatin stars in 
doses of 0.3, 1.0 or 2.0mg/kg were administered at 1 hour prior to onset of operant sessions. 
Training and Ethanol Initiation 
 
Upon arrival, subjects were weighed (start weights: 208 +/-15 g) and handled for a minimum 
of 3 days prior to onset of operant sessions.  Daily sessions were conducted 5 days/week at the same 
time each day during the light portion of the light-dark cycle.  Subjects were initially trained to press 
the lever on a fixed ratio-one schedule that resulted in 15 seconds of access to the sipper tube with 
10% sucrose in 30-minute sessions.  Subjects were water-restricted for the initial two to five sessions 
only, after which food and water were available ad libitum in the home cage.  Over a 3-week period, 
the training/sucrose-fading (Samson, 1986) procedures involved increasing the fixed ratio from 1–4, 
decreasing the sucrose concentration to 1% and, in the ethanol groups, introducing ethanol and 
increasing the concentration from 2% to 10% while fading the sucrose out completely to produce 
final solutions of either 1% Sucrose or 10% Ethanol.  The procedural separation between seeking 
(lever pressing) and consumption was then instituted. Following completion of the single response 
requirement, access to the sipper tube was provided for 20 minutes.  Over 4 weeks, the response 
requirement was increased from 4 lever-presses to 20, and then the response requirement of 20 
was maintained for an additional week.  In order to habituate the rats to the procedure for oral 
administration of drug, subjects were fed gelatin stars containing no drug (vehicle) during the final 
week of training on two occasions, after that day’s behavioral session.  
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Treatment Schedule and Test Sessions 
 The experimental design was similar to the design we have previously used to examine the 
effects of naltrexone and acamprosate in nondependent Long Evans rats (Czachowski and DeLory, 
2009).  Following training, there were alternating daily session treatment “cycles” of drug (a total of 
3 weeks or 14 total sessions from a Tuesday to Friday) and vehicle [a total of 2 weeks or 9 total 
sessions  from a Tuesday to Friday (vehicle exposure was shorter than varenicline exposure since no 
tolerance or sensitization to vehicle was predicted)].  For these daily sessions, the response 
requirement was decreased to a single lever-press to ensure that all subjects would gain access to 
the reinforcer solution (i.e., they would be unlikely to “fail” the response requirement).  At the end 
of each three-week drug and two-week vehicle treatment cycle, a single, non-reinforced extinction 
session was conducted on a Monday (i.e., following 2 days without drug treatment or access to the 
reinforcer solution).  Extinction sessions consisted of 20 minutes of access to the lever, with no 
presentation of the sipper tube spout (however, solutions were present in the sipper tube to control 
for scent cues).  The response requirement was then gradually increased back to 20 for the 
remainder of that week (no treatments) through the following Monday to ensure subjects would 
continue to reliably respond (i.e., that the prolonged exposure to the single response requirement 
schedule did not cause a decrement in responding), and then the next cycle was initiated 
(alternating vehicle and drug).  Each drug treatment cycle consisted of a single dose of varenicline 
assigned to each animal in a balanced design which was repeated 3 times, with the dose changed 
each time, so that at the end of three drug cycles all doses had been tested in all animals.  The entire 
experiment lasted a total of 192 days. 
 
Statistical Analyses 
Total intakes of sucrose and ethanol were determined from the change in fluid volume in the 
graduated cylinder sipper tube, and grams per kilogram of intake were calculated from the intake 
volume, concentration and daily body weight measures.  Total lever-presses as well as a cumulative 
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record of responding were recorded for each session.  For intake, ethanol-reinforced and sucrose-
reinforced groups were analyzed separately (since g/kg differences between ethanol and sucrose 
would be driven by the differences in solution concentration) using repeated measures analysis of 
variance (RM ANOVA), and post hoc comparisons were performed using a Tukey test when 
appropriate.  For seeking, two-way RM ANOVA was used to analyze lever-press responses.  For 
intake data, Dose (four: vehicle plus three drug doses) and Day were the main factors over the first 9 
days.  In addition, mean intake collapsed over the nine (vehicle) or 14 (drug) day treatments was 
analyzed with Dose as the main factor.  For the seeking data, Dose and Reinforcer were the main 
factors.  In both groups, the two vehicle treatment cycles were collapsed for each subject (after 
confirming no differences with paired t-test, see below).  Effect sizes were also calculated for mean 
g/kg intake and mean extinction responding for each dose of varenicline in each reinforcer group.   
 
Results 
 In the Sucrose Group, there were 3 incidents of the sipper tubes air-locking (more likely with 
sucrose than ethanol due to the viscosity of the solution) in 3 different subjects and conditions.  
Their intake data for those days were calculated from the mean of the 2 preceding days (which 
differed by 0.02 g/kg or less).  One subject in the Sucrose Group died with just 5 days remaining in 
the experiment  (with no obvious cause) and 2 different subjects in the Sucrose Group did not 
consistently finish consuming the gelatin star (one at the moderate dose and one at the high dose), 
so these three subjects were removed from the data analyses.  In the Ethanol Group, 2 different 
animals failed to complete the response requirement on a single day (one in the low and one in the 
moderate dose condition) and the remaining 13-day mean was used for the missing data.  One 
subject failed to respond for 3 consecutive days after breaking a toe-nail before the session, and the 
11 remaining days were used for the missing data.  There were no missing extinction data points for 
the Ethanol Group.  Final group sizes were 9 for the Sucrose Group and 12 for the Ethanol Group. 
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 As stated above, t-tests confirmed no differences in the Sucrose or Ethanol Groups for any of 
the intake or seeking measures from the first to the second vehicle treatment cycle, so those data 
were collapsed for a single vehicle measure.  In the ethanol-reinforced group, analysis of ethanol 
intake (g/kg) following vehicle or varenicline over days 1–9 (Fig. 1) showed that there was a main 
effect of Dose [F(3,264)=11.2, p<0.001] with post hoc analyses indicating that the medium and high 
doses differed from vehicle, and the low and high doses differed from each other.  There was also a 
main effect of Day [F(8,264)=3.2, p<0.01] and a Day/Dose interaction [F(24,264)=2.2, p<0.001].  Post 
hoc analyses indicated that the effect of Day was due to increased overall intake on Day 5 relative to 
Days 1, 6 and 9 (likely a slight “Monday” rebound effect following the two days of no sessions – Day 
5 was the only Monday drinking session for all groups/conditions).  The Day/Dose interaction 
showed that there were no differences in intake across treatments on Days 1 or 2, however, on Days 
3-5 intake following all varenicline doses was significantly lower than following vehicle.  The high 
dose continued to differ from vehicle over the remaining Days, and also differed from the low dose 
on Days 5-9 and the medium dose differed from vehicle again on Day 8.  Analysis of total mean 
ethanol intake collapsed over all days similarly showed a main effect of Dose [F(3,33)=14., p<0.001], 
with post hoc analyses confirming that both the medium and high doses differed from vehicle and 
that the high and low doses were also significantly different from each other. 
In the sucrose-reinforced group, analysis of sucrose intake (g/kg) following vehicle or 
varenicline (Fig. 2) over days 1–9 showed no main effect of Dose [F(3,192)=1.1, p=0.37].  However, 
there was a main effect of Day [F(8,192)=5.7, p<0.001] and a Day/Dose interaction [F(24,192)=3.1, 
p<0.001].  Post hoc analyses indicated that the effect of Day was due to an overall decrease in intake 
over days (Day 1 vs. 5, 6, 8 and 9, Day 2 vs.  9, Day 3  vs. 8 and 9).  However, the Day/Dose 
interaction showed that when Days within Dose were examined, intake was stable across the vehicle 
treatment.  There were only sporadic effects of varenicline when examined within Days, such that 
there was a significant effect of the high dose of varenicline relative to vehicle on Days 1, 6 and 9.  
On Day 6, the medium dose and vehicle also differed, while there were no differences between the 
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low dose and vehicle on any Day.  Analysis of total mean sucrose intake collapsed over all days 
showed no main effect of Dose [F(3,24)=2.2, p=0.12].   
Analysis of the seeking response assessed lever-presses on the extinction test days and 
revealed no difference in number of responses between the Sucrose and Ethanol Groups 
[F(1,57)=1.2, p=0.28], no main effect of Dose [F(3,57)=1.9, p=0.15] and no interaction between 
Reinforcer and Dose [F(3,57)=0.5, p=0.70].  There was also no difference in latency to first lever-
press between the sucrose and ethanol Reinforcers [F(1,57)=1.1, p=0.30], no main effect of Dose 
[F(3,57)=0.2, p=0.89], and no interaction between Reinforcer and Dose [F(3,57)=0.3, p=0.86].  
Similarly, an analysis of the average latency to first lick on the intake treatment days confirmed that 
there was also no difference between the sucrose and ethanol Reinforcers [F(1,57)=1.6, p=0.22], no 
main effect of Dose [F(3,57)=1.4, p=0.24], and no interaction between Reinforcer and Dose 
[F(3,57)=0.7, p=0.55].   
Overall effect sizes were larger in the Ethanol Group than in the Sucrose Group, and in fact 
were nearly nonoverlapping between Groups within both the drinking and seeking responses across 
varenicline doses (see Table 1).  
 
Discussion 
The behavioral paradigm used here presented rats with long-term (3 weeks) exposure to 
ethanol consumption with varenicline “on board”, and then tested the effects of this experience on 
subsequent ethanol-seeking as a measure of “craving” at a time when varenicline would no longer 
have been pharmacologically active.  Importantly, the model also separates seeking and drinking for 
distinct measures of each reinforcer-directed behavior, and the self-administration of varenicline by 
the oral route avoids the stress effects of multiple injections.  Varenicline is well absorbed after oral 
administration and has a bioavailability of greater than 87% (Goodman and Gilman, 2011; Obach et 
al., 2005).  While it is primarily considered a partial agonist at α4β2 and full agonist at α7 nicotinic 
cholinergic receptors, it should be noted that varenicline also has agonist activity at serotonin (5HT3) 
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receptors (Lummis et al., 2011; Price et al., 2015).  It has previously been shown that a 2.0 mg/kg 
dose of oral varenicline at 1 hour prior to onset of ethanol access (-2hr pretreat was less effective) 
decreases free access intake of ethanol in male P rats (Froehlich et al., 2016).  The present findings 
extend these observations and illustrate that the effect of varenicline on ethanol intake is both dose-
dependent and selective for ethanol self-administration.  Specifically, 0.3, 1.0 and 2.0 mg/kg doses 
decreased ethanol self-administration over several individual days of testing.  This effect emerged on 
day 3 for all doses, and then persisted though the remaining test days for the medium and high 
doses.  This effect was also apparent in the collapsed measure of ethanol consumption across all 
days. 
The fact that the first two days of treatment resulted in no decrement in self-administration 
suggests that, like naltrexone, the effects of varenicline may be related to its ability to interfere with 
the rewarding properties of ethanol.  This apparent “reward-blocking” effect of varenicline is 
consistent with a recent report in humans that consumed high doses of alcohol during varenicline 
treatment and reported greatly reduced subjective intoxication that was dose-dependent and long-
lasting (Verplaetse et al., 2016a).  Our findings are also consistent with those of Randall et al. (2015) 
who found no effect of a single, acute administration of varenicline on operant responding in Long 
Evans rats given doses of varenicline that did not interfere with motor performance (i.e., 0.3 and 1.0 
mg/kg).  Notably, the reinforcer in that paradigm was sweetened ethanol (2% sucrose/15% ethanol) 
and the operant response was a fixed ratio of two responses (FR2), so it was a “mixed” 
seeking/drinking response unlike the purely drinking response utilized in the present study.  
Steensland et al. (2007), on the other hand, showed that both a 1.0 and 2.0 mg/kg dose were 
effective in decreasing operant responding for ethanol even on the first day of acute treatment, 
however the operant paradigm required three lever presses for a “sip” of ethanol.  Attenuation of 
ethanol drinking in the present study is not likely to be due to any motor impairing effects of 
varenicline, since there were no differences between vehicle and treatment in the time to first lever-
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press or the time to first lick (these are not explicitly measures of locomotion, but making the first 
lick does require the animal to traverse to the opposite side of the operant chamber). 
Overall, there was no attenuation of sucrose intake by varenicline when analyzed across all 
days of testing.  There were only sporadic effects of the medium and high doses on specific days that 
did not suggest any pattern of varenicline efficacy.  Using Cohen’s (1969) general characterization of 
effect sizes of 0.2 as “small”, 0.5 as “medium” and 0.8 as “large”, the effect of varenicline on sucrose 
drinking was in the medium range (0.34-0.74 over all doses) whereas the effect size for ethanol 
drinking was in excess of large (0.67-1.81 over all doses).  These results are consistent with, and 
extend the findings of, Steensland et al. (2007) by showing specific effects of varenicline on a mixed 
seeking/drinking response for ethanol and not for sucrose.  The present results are also consistent 
with the recent findings of Holgate and colleagues (2017) who showed that varenicline decreased 
free-access intake of ethanol to a much greater degree and for a longer period of time as compared 
to sucrose. 
The tests of reinforcer-seeking were conducted in animals with reinforcer-plus-varenicline 
exposure, but with no varenicline currently “on board”.  The expectation was that sufficient 
exposure to pairings of reinforcer-plus-varenicline would impact overall subjective reinforcer effects, 
ideally specifically ethanol but not sucrose, and thereby decrease subsequent reinforcer-seeking 
indicating a reduction in “craving”.  Overall, we found that the effects of varenicline on the 
response/reinforcer association were not strong enough to interfere with goal-directed responding 
after the termination of varenicline treatment.  It has previously been shown that a high dose of 
varenicline has some carry over effects in that it has a tendency to decrease 2-hour free choice 
ethanol intake one day following cessation of  treatment (Froehlich et al., 2016), but these effects 
were not apparent two days later.  Notably, in that study, intake of ethanol on that first day in the 
absence of varenicline would have given subjects exposure to ethanol alone which would be 
expected to facilitate a return to normal drinking.   
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In the present study, there were some indications that varenicline had specific effects on 
ethanol-seeking.  There was some decrement of ethanol-seeking across all doses (an average of 72-
83% relative to vehicle as compared to 82-93% in the Sucrose Group), however, this was not 
sufficient to reach statistical significance.  On the other hand, effect sizes indicate a low to medium 
effect of varenicline on sucrose seeking (0.30-0.59) and a medium to large effect on ethanol-seeking 
(0.53-0.82).  Note that Randall et al. (2015) showed that varenicline does not substitute for ethanol 
and our data support that conclusion.  The decrease in ethanol drinking we observed is not due to 
varenicline substituting for, or enhancing, the reinforcing properties of ethanol, since subsequent 
reinforcer-seeking does not increase, but actually decreases slightly.  Taken together, our findings 
show that varenicline blocks some rewarding properties of ethanol, but that it is important for 
varenicline to be “on board” to observe strong and sustained effects of the drug on subsequent 
ethanol craving.  This is consistent with recent findings in humans showing that lower doses of 
varenicline do not decrease alcohol craving as effectively as higher doses and that there is  a direct 
relationship between plasma levels of varenicline and number of drinks consumed (Verplaetse et al., 
2016b).  Given that varenicline is well-tolerated, that previous concerns regarding potential 
cardiovascular effects have been disproven (Aubin and Luquiens, 2015; Prochaska and Hilton, 2012), 
and that both the preclinical and clinical evidence continues to support the fact that varenicline is 
effective at decreasing ethanol-directed behaviors, it appears to be a good pharmacotherapeutic 
tool for treating alcohol use disorders at this time.  Moreover, optimal combinations of varenicline 
with other medications may be the ultimate solution for targeting alcohol-specific craving and binge 
drinking (e.g., Froehlich et al., 2016).   
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Figure Legends 
Fig 1.  In the ethanol-reinforced group (n=12), mean (±SEM) ethanol intake (g/kg) over days 
following either vehicle or varenicline treatment (data from days preceding the dotted line were 
analyzed by Day and Dose).  Inset:  Total mean (±SEM) ethanol intake collapsed over all days. One 
asterisk indicates a main effect of treatment and significant difference relative to vehicle, two 
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indicate a difference relative to both vehicle and the low dose.  See text for specific effects of doses 
on individual days. 
 
Fig 2.  In the sucrose-reinforced group (n=12), mean (±SEM) sucrose intake (g/kg) over days 
following either vehicle or varenicline treatment (data from days preceding the dotted line were 
analyzed by Day and Dose).  Inset:  Total mean (±SEM) sucrose intake collapsed over all days.  See 
text for specific effects of doses on individual days. 
  
Fig. 3. Mean (±SEM) lever-press responses during single, nonreinforced extinction sessions in the 
ethanol and sucrose groups (as indicated) following prior exposure to vehicle or varenicline during 
reinforced sessions. 
Table 1. 
Mean latency to first lick and latency to first lever press in seconds (±SEM) listed by increasing dose 
(0, 0.3, 1.0 and 2.0 mg/kg varenicline) for the Ethanol and Sucrose Groups. 
 
 Lick Latency (± SEM) Lever-Press Latency (± SEM) 
Ethanol Group 4.2 (1.6)  5.3 (1.8)  5.5 (1.7)  21.0 (14.5) 67.3 (41.6)  40.5 (15.9)  47.1 (23.2)  64.4 (47.4)  
Sucrose Group 1.6 (0.4)  1.3 (0.1)  1.6 (0.2)  4.4 (2.1) 24.1 (6.4)  23.2 (6.5)  19.2 (8.1)  16.1 (6.1) 
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Table 2. 
Varenicline effect sizes for each behavior (drinking and seeking) listed by increasing dose (0.3, 1.0, 
2.0) for the Ethanol and Sucrose Groups. 
 
 Drinking Seeking 
Ethanol Group 0.67,  1.21,  1.81 0.82,  0.71,  0.53 
Sucrose Group 0.52,  0.34,  0.74 0. 30,  0.59,  0.42 
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